18431 and 32374, novel human protein kinase family members and uses therefor
AssigneeMillennium Pharmaceuticals, Inc.
InventorsRachel Meyers, Rosana Kapeller-Libermann, Immaculada Silos-Santiago
Life of this patent
Estimating the term…
Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsRachel Meyers, Rosana Kapeller-Libermann, Immaculada Silos-Santiago
Estimating the term…
The invention provides isolated nucleic acids molecules, designated 32374 or 18431 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32374 or 18431 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32374 or 18431 gene has been introduced or disrupted. The invention still further provides isolated 32374 or 18431 proteins, fusion proteins, antigenic peptides and anti-32374 or -18431 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
An isolated 32374 or 18431 nucleic acid molecule selected from the group consisting of:
An isolated 32374 or 18431 polypeptide selected from the group consisting of:
A method for identifying a compound capable of treating a disorder characterized by aberrant 32374 or 18431 nucleic acid expression or 32374 or 18431 polypeptide activity comprising assaying the ability of the compound to modulate 32374 or 18431 nucleic acid expression or 32374 or 18431 polypeptide activity, thereby identifying a compound capable of treating a disorder characterized by aberrant 32374 or 18431 nucleic acid expression or 32374 or 18431 polypeptide activity.
A method for evaluating the efficacy of a treatment of a disorder, in a subject, comprising:
Dependencies are inferred from the claim text.